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Visceral leishmaniasis 
research: operational 
focus needed
The UK Department for International 
Development has launched the first 
ever large-scale eﬀ ort, KalaCORE,1 to 
control visceral leishmaniasis. Funding 
of up to £26·3 million will be provided 
to tackle visceral leishmaniasis in 
south Asia and east Africa, the two 
endemic regions with more than 85% 
of the global visceral leishmaniasis 
cases. Through KalaCORE, more 
than 250 000 cases are hoped to be 
treated, averting 55 000 deaths. In 
east Africa, support will aim to reduce 
the burden of visceral leishmaniasis, 
whereas support in south Asia will 
focus on complementing ongoing 
national eﬀ orts to eliminate visceral 
leishmaniasis.1 
Greg Matlashewski and colleagues2 
(December, 2014, issue) emphasise 
research priorities for visceral 
leishmaniasis elimination, which 
include the assessment of improved 
and shorter drug regimens, the role 
of asymptomatic and post-kala 
azar dermal leishmaniasis cases in 
disease epidemiology, and vaccine 
development. Undoubtedly, these 
are important research priorities. 
However, three research areas 
crucial to the success of operational 
programmes, such as KalaCORE, are 
not discussed, and—if omitted—could 
hamper any substantial progress in the 
tackling of the visceral leishmaniasis 
burden worldwide. 
First, there is no mention of 
insecticide and drug resistance, both 
of which are particularly prevalent 
in the Indian subcontinent.3,4 How 
resistance aﬀ ects the eﬀ ect of vector 
control eﬀ orts (ie, insecticide-treated 
bednets and indoor residual spraying 
of households with insecticide) and 
case management in an operational 
context, and how programme failure 
relates to actual resistance versus poor 
programme implementation (eg, 
suboptimum spraying of households 
with insecticide or non-compliance of 
patients to anti-leishmania drugs) are 
equally important questions. Second, 
aspects relevant to the surveillance 
of visceral leishmaniasis are not 
discussed. Research in this area could—
similar to other neglected tropical 
diseases5—include the development of a 
standardised approach for mapping and 
surveillance of visceral leishmaniasis 
to improve our understanding of its 
distribution and endemicity, which 
presently relies on passively reported in-
country case notiﬁ cations.6 Moreover, 
visceral leishmaniasis is not necessarily 
a notiﬁ able disease; approaches should 
be developed and piloted to ensure 
that all cases of visceral leishmaniasis 
are detected and reported. Rigorous 
reporting will become particularly 
important if transmission intensity 
decreases (eg, in Nepal and Bangladesh) 
and elimination becomes a real 
possibility. Finally, operational research 
should assess how diagnostic testing 
could be operationalised in health 
facilities that already provide services 
for malaria or tuberculosis; areas 
sympatric for visceral leishmaniasis and 
malaria could be prioritised for vector 
control. 
Research that addresses the above-
mentioned operational questions 
and challenges would ensure that 
programmes such as KalaCORE will 
yield maximum effect, especially as 
these programmes remain few and far 
between.
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